Registration Number
0222U005299,
0119U103007
, R & D reports
Title
Determine the role of cyclooxygenase-2 inhibitors in combination with cytostatics in radiomodification of radiation therapy for non-small cell lung and squamous cell carcinoma of the head and neck
popup.stage_title
Head
Mitryaeva Nataliya A., Доктор біологічних наук
Starenkiy Viktor P., Доктор медичних наук
Registration Date
27-12-2022
Organization
State Organization "Grigoriev Institute for Medical Radiologiy of the National Academy of Medical Sciences of Ukraine"
popup.description2
The object of study: the effectiveness of radiation therapy (RT) in combination with the COX-2 inhibitor and cisplatin in patients with non-small cell lung cancer (NSCLC) and squamous cell cancer of the head and neck (PRGН) with determination of the content of VEGF, COX-2, PGE-2 in blood serum. The aim of the work: is to increase the effectiveness of radiation therapy of non-small cell lung cancer and squamous cell carcinoma of the head and neck by radiomodification with cyclooxygenase-2 inhibitors (celecoxibs) in combination with cytostatics (cisplatin) based on determining the mechanisms of their radiosensitizing action. Methods of research and equipment: clinical, instrumental, statistical; the immunoenzymometric analyzer, the linear accelerator. Theoretical and practical results: when RT is used in combination with a COX-2 inhibitor and cisplatin in patients with NSCLC, the frequency of regressions increases by 18,9%, reaching 88,9%, annual recurrence-free survival increases by 26,6% compared to RT in combination with a COX-2 inhibitor. Local radiation reactions and hematological toxicity do not exceed II degree. Such a scheme allows improving the results of treatment due to complete regressions (40,0%) in patients with PRGН. Radiation reactions of the III degree were noted in 20,0% of cases. Novelty: it was proven for the first time that with various schemes of RT using radiomodifiers in patients with NSCLC and PRGН, there is a decrease in the level of VEGF, PGE-2 and COX-2, which indicates the strengthening of the antiangiogenic effect, which is more pronounced with the combined effect of irradiation, cisplatin and celecoxib. Recommendations have been developed for a new technology of radiation treatment by means of radiomodification with celecoxib and cisplatin in patients with NSCLC and PRGН. Effectiveness of implementation: increasing the duration of the relapse-free period and improving the quality of life of patients. Domain of usage: radiation oncology.
Product Description
popup.authors
Artiukh Serhii Volodymyrovych
Bilozor Nataliia Volodymyrivna
Bilchenko Iryna Viktorivna
Grebinyk Lidiya Volodymyrivna
Kolomatska Viktoriia Volodymyrivna
Kondrashova Olena Ivanivna
Makaruk Olena Viktorivna
Potapova Tetiana Ivanivna
Pshyshevska Liudmyla Anatoliivna
Tkachenko Alla Anatoliivna
popup.nrat_date
2022-12-27
